Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00837876 · ClinicalTrials.gov registry record · Phase 2
Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery
A Phase 2 study of Pancreatic Cancer, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
- 6
- Study locations
NCT00837876 is a Phase 2 study of Pancreatic Cancer that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 37 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 2 states.
The verdict
NCT00837876, a Phase 2 study of Pancreatic Cancer, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
- 6
- Study locations
Study Summary
RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving sorafenib together with erlotinib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving sorafenib together with erlotinib works in treating patients with pancreatic cancer that cannot be removed by surgery.
Conditions Studied
Interventions
- DRUG Sorafenib
- DRUG Erlotinb
Study Locations (6)
Tennessee
- Erlanger Cancer Center at Erlanger Hospital - Baroness - Chattanooga
- Baptist Regional Cancer Center at Baptist Riverside - Knoxville
- Vanderbilt-Ingram Cancer Center - Cool Springs - Nashville
- Vanderbilt-Ingram Cancer Center at Franklin - Nashville
- Vanderbilt-Ingram Cancer Center - Nashville
Kentucky
- Purchase Cancer Group - Paducah - Paducah
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2008-10 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00837876
The ClinicalTrials.gov registry entry for NCT00837876 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Sorafenib is the first listed.
NCT00837876 reports 6 study locations spanning 2 distinct geographic areas - top geographies include Tennessee, Kentucky.
Frequently Asked Questions
What is clinical trial NCT00837876 about?
NCT00837876 is a clinical study titled "Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery". RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving sorafenib together with erlotinib may kill more tumor cells. PURPOSE: This phas...
What is the current status of trial NCT00837876?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2008-10. Estimated completion is 2012-11.
What conditions does trial NCT00837876 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT00837876?
The interventions under investigation include: Sorafenib (DRUG), Erlotinb (DRUG).
Who is sponsoring clinical trial NCT00837876?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00837876 being conducted?
This trial has 6 study locations across Kentucky, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.